Fraksiparin - instruction , application reviews

Contents:

1. active substance

2. Product form

3. Composition

4. Indications

5. Contraindications

6. dosage and Administration

7. Side effects

8. Cautions

9. Terms and Conditions of storage

Fraksiparin - anticoagulant direct action.

active substance

nadroparin calcium (Nadroparincalcium)

Product form

drug released as a clear, pale yellow or colorless injection solution, which is being implemented in disposable syringes for 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9and 1 ml in the syringe blisters 2 in cartons (1 or 5 blisters each).

Composition

1 syringe

calcium nadroparin

2850, 3800, 4750, 5700, 6650, 7600, 8550 or 9500 IU of anti-Xa

Excipients: calcium hydroxide solution or dilute hydrochloric acid, water for injection.

Indications Indications for use Fraksiparina are:

  • treatment of thromboembolism.
  • Treatment of myocardial infarction without Q-wave MI and unstable angina therapy.
  • prevention of blood clotting in the backgr
    ound hemodialysis.
  • prevention of thromboembolic events (patients with a high probability of thrombosis in heart or acute respiratory failure; orthopedic and surgical interventions).

Contraindications The drug is contraindicated in the following situations:

  • Acute bacterial endocarditis.
  • Intracranial hemorrhage.
  • Surgeries or injuries to the eyes, spinal cord and brain.
  • Signs of bleeding.
  • bleeding tendency associated with impaired hemostasis.
  • Thrombocytopenia caused by the use of nadroparin in history.
  • Organic organ damage, accompanied by bleeding (for example, acute ulcer 12 duodenal ulcer or stomach).
  • severe renal insufficiency.
  • Children under 18 years old.
  • hypersensitivity to the drug.

Fraksiparin With caution is prescribed in situations that are associated with an increased likelihood of bleeding:

  • Renal failure.
  • Liver failure.
  • severe hypertension.
  • blood circulation in the retina and choroid.
  • peptic ulcer or a history of other diseases with a high risk of bleeding.
  • postoperative period after surgery on the eyes, spinal cord and brain.
  • duration of treatment.
  • Failure to follow the recommended treatment conditions.
  • simultaneous administration of drugs that increase the risk of bleeding.
  • body weight less than 40 kg.

Dosage and Administration

Fraksiparin injected subcutaneously in the abdomen, alternating right and left sides.Also, it allowed the introduction of the drug in the thigh.The needle must enter perpendicular jammed in the crease of the skin.After injection, the injection site need not rubbed.

for prevention of thromboembolism in surgery nadroparin administered at a dose of 0.3 ml.The drug is used for 2-4 hours prior to surgery, and then - 1 times per day.Duration of therapy is at least 7 days (until the transfer of the patient to outpatient treatment).If

thromboembolism prophylaxis in orthopedic practice drug is administered at a dose that is set depending on the weight of the patient based 38 IU / kg.On postoperative day 4 the dose may be increased by 50%.The first introduction of Fraksiparina carried out 12 hours before surgery, and the second - 12 hours after surgery.Then, the drug is used 1 time per day to transfer the patient to outpatient treatment.Minimum course of treatment is 10 days.

persons with an increased risk of thrombosis nadroparin is administered 1 time per day.Patients whose weight exceeds 70 kg, the drug is administered at 0.4 mL.If body weight less than 70 kg, the drug is administered at a dose of 0.6 ml.Nadroparin apply throughout the period of the likelihood of thrombus formation.

Myocardial infarction without tooth Q, as well as unstable angina drug is administered subcutaneously twice daily.Duration of therapy usually is 6 days.In some situations Fraksiparin combined with aspirin (325 mg daily).Nadroparin initial dose administered as an intravenous bolus injection, and the subsequent doses are administered subcutaneously.Dose is determined depending on the patient's weight based on 1 IU 86 kg.

the treatment of thromboembolism anticoagulants in tablet form to be taken as soon as possible.nadroparin treatment lasts until the desired index of prothrombin time.In this situation, the preparation is applied twice daily at a dose of 86 IU / kg body weight.The standard duration of treatment course is 10 days.

To prevent blood clotting in the dialysis dose Fraksiparina background set on an individual basis, taking into account the technical conditions of the dialysis.At the beginning of each preparation procedure is introduced into the arterial line of a dialysis loop once.For those without increased likelihood of bleeding initial dose set depending on the weight if body weight less than 50 kg, the dose is 0.3 ml;if the weight varies from 50 to 69 kg, the dose of nadroparin 0.4 mL;if the body weight exceeds 70 kg, the dose is 0.6 ml.For patients at high risk of bleeding is allowed to use only 50% of the recommended dose.If the dialysis procedure lasts more than 4 hours, then designate additional small doses of nadroparin.

In elderly patients, a dose adjustment is required.Before treatment is necessary to monitor the performance of the kidneys.

When mild to moderate renal insufficiency for the prevention of thrombosis dose adjustment is required, and in severe renal insufficiency Fraksiparina reduce the dose by 25%.

When mild to moderate renal insufficiency for the prevention and treatment of thromboembolism dose reduced by 25%, and patients with severe renal insufficiency is contraindicated nadroparin.

Side effects

Application Fraksiparina may cause adverse reactions such as:

  • hematopoietic system: thrombocytopenia, eosinophilia, reversible upon discontinuation of therapy.
  • immune system: hypersensitivity reactions (skin reactions, angioedema).
  • Hepatobiliary system: transient increase in liver transaminases.
  • blood coagulation system: bleeding of various localizations.
  • Local reactions: dense nodules, subcutaneous hematoma, or skin necrosis at the injection site.The development of necrosis, usually preceded by purpura or infiltrated or painful erythematous spot.
  • Other: reversible hyperglycemia, priapism.

main symptom of overdose is bleeding.Minor bleeding does not need special treatment.In severe cases, resorted to protamine sulfate.The dose of the antidote is calculated taking into account the time that has elapsed after the administration Fraksiparina.

Cautions

product is not intended for intramuscular injection.

During therapy nadroparin should be carefully monitored for platelet count, since the use of heparin often causes thrombocytopenia.Sometimes drug analyzed leads to the development of severe thrombocytopenia.In this case, treatment should be discontinued immediately Fraksiparinom.If there is background heparin therapy of thrombocytopenia, in this situation it is necessary to resort to other anticoagulants groups.

Nadroparin can suppress the production of aldosterone, which leads to the development of hyperkalemia, especially when it comes to patients with elevated levels of potassium in the blood or for patients predisposed to hyperkalemia (ie, persons with metabolic acidosis, chronic renal insufficiency, diabetes mellitusas well as people who take drugs that cause hyperkalemia).Patients who are at risk for therapy must regularly monitor blood potassium.

During the traumatic or repeated spinal or epidural puncture as well as in patients with established epidural catheters or concomitant use of other drugs that affect hemostasis (anticoagulants, antiplatelet agents, non-steroidal anti-inflammatory drugs), the risk of epidural / spinal hematoma is increased.

When epidural / spinal anesthesia or lumbar puncture between administrations Fraksiparina must complete 12 hours of prophylaxis or 24 hours for medicinal purposes.People suffering from renal insufficiency, the data slots can be increased.In order to detect early signs and symptoms of neurological disorders, should closely monitor the patient's condition.

the treatment and prevention of venous thromboembolism, hemodialysis and prevention of clotting nadroparina simultaneous use with antiplatelet agents and NSAIDs increases the likelihood of bleeding.

Terms and Conditions of storage

Keep out of direct sunlight and protected from children, at a temperature not exceeding 30 ° C.

Shelf life - 3 years.

After the expiry date of the drug use is unacceptable.

Attention!

Product description posted on this page is a supplement and a simplified version of the official version of the annotations to the drug.The information is provided for informational purposes only and is not a guide to self-medication.Before using the product you should consult with a specialist and to get acquainted with the instructions approved by the manufacturer.

Latest Blog Post

The drug Penkrofton - instructions for use and feedback
August 12, 2017

Contents: 1. composition and the form of the drug Penkrofton 2. Pharmacological action Penkroftona 3. Indications 4. Dosage P...

Penzital - instruction , application reviews
August 12, 2017

Contents: 1. Pharmacological action 2. application features Penzitala 3. Instruction Penzitalu: method of use and dosage 4. r...

Penester - instruction , application reviews
August 12, 2017

Contents: 1. structure and pharmacological action 2. Instruction Penesteru - indications for use 3. Further guidance on the appli...